425 related articles for article (PubMed ID: 26923330)
1. Targeting the RB-E2F pathway in breast cancer.
Johnson J; Thijssen B; McDermott U; Garnett M; Wessels LF; Bernards R
Oncogene; 2016 Sep; 35(37):4829-35. PubMed ID: 26923330
[TBL] [Abstract][Full Text] [Related]
2. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
3. Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.
Michaloglou C; Crafter C; Siersbaek R; Delpuech O; Curwen JO; Carnevalli LS; Staniszewska AD; Polanska UM; Cheraghchi-Bashi A; Lawson M; Chernukhin I; McEwen R; Carroll JS; Cosulich SC
Mol Cancer Ther; 2018 May; 17(5):908-920. PubMed ID: 29483206
[TBL] [Abstract][Full Text] [Related]
4. Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.
Condorelli R; Spring L; O'Shaughnessy J; Lacroix L; Bailleux C; Scott V; Dubois J; Nagy RJ; Lanman RB; Iafrate AJ; Andre F; Bardia A
Ann Oncol; 2018 Mar; 29(3):640-645. PubMed ID: 29236940
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
6. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.
Spring L; Bardia A; Modi S
Discov Med; 2016 Jan; 21(113):65-74. PubMed ID: 26896604
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.
Dean JL; Thangavel C; McClendon AK; Reed CA; Knudsen ES
Oncogene; 2010 Jul; 29(28):4018-32. PubMed ID: 20473330
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
Scott SC; Lee SS; Abraham J
Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
[TBL] [Abstract][Full Text] [Related]
9. Targeting breast cancer with CDK inhibitors.
Mayer EL
Curr Oncol Rep; 2015; 17(5):443. PubMed ID: 25716100
[TBL] [Abstract][Full Text] [Related]
10. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers.
Finn RS; Aleshin A; Slamon DJ
Breast Cancer Res; 2016 Feb; 18(1):17. PubMed ID: 26857361
[TBL] [Abstract][Full Text] [Related]
11. Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
Hecht KA; Selby C
Ann Pharmacother; 2019 Feb; 53(2):195-203. PubMed ID: 30079740
[TBL] [Abstract][Full Text] [Related]
12. [CDK4/6 inhibitors: biomarkers, mechanisms of resistance and interest of the study of the circulating tumor DNA].
Gonçalves A
Bull Cancer; 2018 Jun; 105(6):545-546. PubMed ID: 29729807
[No Abstract] [Full Text] [Related]
13. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
Laderian B; Fojo T
Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment (Review).
Liu M; Liu H; Chen J
Oncol Rep; 2018 Mar; 39(3):901-911. PubMed ID: 29399694
[TBL] [Abstract][Full Text] [Related]
15. HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in Cancer.
Zhou Y; Jin X; Ma J; Ding D; Huang Z; Sheng H; Yan Y; Pan Y; Wei T; Wang L; Wu H; Huang H
Cancer Res; 2021 Mar; 81(6):1486-1499. PubMed ID: 33419772
[TBL] [Abstract][Full Text] [Related]
16. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
17. A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer.
Malorni L; Piazza S; Ciani Y; Guarducci C; Bonechi M; Biagioni C; Hart CD; Verardo R; Di Leo A; Migliaccio I
Oncotarget; 2016 Sep; 7(42):68012-68022. PubMed ID: 27634906
[TBL] [Abstract][Full Text] [Related]
18. Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer.
Owsley J; Jimeno A; Diamond JR
Drugs Today (Barc); 2016 Feb; 52(2):119-29. PubMed ID: 27092341
[TBL] [Abstract][Full Text] [Related]
19. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
[TBL] [Abstract][Full Text] [Related]
20. The Role of CDK4/6 Inhibition in Breast Cancer.
Murphy CG; Dickler MN
Oncologist; 2015 May; 20(5):483-90. PubMed ID: 25876993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
